SCHEMBL13698487

SCHEMBL13698487

COc1ccc(Cl)cc1N1CCN(CC2CC3C=CC2C3)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.62
DRD4 P21917 4/20 0.62
KDM4E B2RXH2 8/20 0.53
TSHR P16473 1/20 0.53
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HTT P42858 1/20 0.50
HTR3E A5X5Y0 1/20 0.49
HTR3B O95264 1/20 0.49
HTR3A P46098 1/20 0.49
HTR3D Q70Z44 1/20 0.49
HTR3C Q8WXA8 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
ATM Q13315 1/20 0.47
POLB P06746 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3973853 0.88 KDM4E (0.57) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL13698484 0.87 KDM4E (0.53) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL13698510 0.85 KDM4E (0.56) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL3972625 0.84 DRD2 (0.46) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL13698455 0.84 KDM4E (0.64) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL13764660 0.82 KDM4E (0.52) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL12896836 0.81 MEN1 (0.47) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL12897988 0.81 MEN1 (0.47) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL13698542 0.81 KDM4E (0.56) DRD2DRD4KDM4ETSHRALDH1A1
SCHEMBL12897635 0.79 KDM4E (0.44) DRD2DRD4KDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 US disclosed
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 DRD2 506/4885DRD4 1095/4885KDM4E 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.